Ginkgo Bioworks vs Regenxbio
DNA and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNA and RGNX compare
Ginkgo Bioworks is the larger company, worth 1.3 times as much as Regenxbio ($647M against $504M).
Regenxbio grew revenue faster over the last twelve months (12.0% versus −13.2% for Ginkgo Bioworks).
Regenxbio keeps more of each dollar of sales as profit, with a net margin of −113% compared with −192% at Ginkgo Bioworks.
Ginkgo Bioworks scores higher on the StockData Score (9 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNA | RGNX |
|---|---|---|
| Size and price | ||
| Market cap | $647M | $504M |
| Share price | $9.61 | $7.64 |
| Change, 1 year | 15.0% | −34.1% |
| Change, 5 years | −98.2% | −77.2% |
| Beta (5Y) | 2.73 | 1.78 |
| Employees | 485 | 371 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.9× | 2.9× (better) |
| P/B | 1.6× (better) | 7.0× |
| FCF yield | −26.8% (better) | −49.5% |
| Fair value | $9.67 | – |
| Margin of safety | 0.61% | – |
| Growth | ||
| Revenue growth (TTM) | −13.2% | 12.0% (better) |
| Revenue growth, 5Y average | 17.3% (better) | 2.0% |
| Profitability | ||
| Operating margin | −205% | −94.1% (better) |
| Net margin | −192% | −113% (better) |
| FCF margin | −133% (better) | −143% |
| Return on equity | −52.7% (better) | −138% |
| Return on invested capital | −113% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −3.9× |
| Current ratio | 4.72 (better) | 2.86 |
| Altman Z-score | −9.15 | −3.83 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 53.7% | 64.2% |
| Held by insiders | – | 7.6% |
| Insider net buying, 12 months | −$5.0M | $9.6K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 16.7% |
Go deeper
- DNA stock overview
- DNA income statement
- DNA valuation and score
- RGNX stock overview
- RGNX income statement
- RGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.